These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16236069)

  • 1. The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs.
    Fabbri A; Aversa A
    Int J Androl; 2005 Dec; 28 Suppl 2():69-73. PubMed ID: 16236069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
    Axilrod AC
    Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Centrally acting mechanisms for the treatment of male sexual dysfunction.
    Miner MM; Seftel AD
    Urol Clin North Am; 2007 Nov; 34(4):483-96, v. PubMed ID: 17983889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Carson CC; Lue TF
    BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic dilemma: how to use tadalafil.
    Carosa E; Lombardo F; Martini P; Brandetti F; Jannini EA
    Int J Androl; 2005 Dec; 28 Suppl 2():74-80. PubMed ID: 16236070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST
    Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
    de Tejada IS
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S40-2. PubMed ID: 15224136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Novel indications for phosphodiesterase type 5 inhibitors].
    Rosenkranz S; Caglayan E; Erdmann E
    Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.
    Sussman DO
    J Am Osteopath Assoc; 2004 Mar; 104(3 Suppl 4):S11-5. PubMed ID: 15083994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
    Kloner RA
    Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving role of testosterone in the treatment of erectile dysfunction.
    Shabsigh R; Rajfer J; Aversa A; Traish AM; Yassin A; Kalinchenko SY; Buvat J
    Int J Clin Pract; 2006 Sep; 60(9):1087-92. PubMed ID: 16939550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials.
    Blonde L
    Curr Med Res Opin; 2006 Nov; 22(11):2111-20. PubMed ID: 17076971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease].
    Bryniarski L; Rzepecki M; Klocek M; Wyczołkowski M
    Przegl Lek; 2009; 66(4):192-7. PubMed ID: 19708509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of erectile dysfunction in the primary care setting.
    Rosenberg MT
    Int J Clin Pract; 2007 Jul; 61(7):1198-208. PubMed ID: 17577299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
    Wright PJ
    Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction.
    Ishii N; Nagao K; Fujikawa K; Tachibana T; Iwamoto Y; Kamidono S
    Int J Urol; 2006 Aug; 13(8):1066-72. PubMed ID: 16903931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.
    Francis SH; Morris GZ; Corbin JD
    Int J Impot Res; 2008; 20(4):333-42. PubMed ID: 18418391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.